Herpes simplex virus (HSV) immediate-early (IE) promoter-directed reporter system for the screening of antiherpetics targeting the early stage of HSV infection

Journal of Biomolecular Screening

Volumn 15, Issue 8, 2010, Pages 1016-1020

  Zhu, Qin Chang ^a   Wang, Yi ^a   Peng, Tao ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

drug screening; entry inhibitors; HSV; IE promoter; microbicides

Indexed keywords

ACICLOVIR; DEXTRAN SULFATE; FOSCARNET SODIUM; IMMEDIATE EARLY PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DISEASE COURSE; DRUG SCREENING; DRUG TARGETING; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; VERO CELL;

ALGORITHMS; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; HERPES SIMPLEX; IMMEDIATE-EARLY PROTEINS; MOLECULAR TARGETED THERAPY; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; TRANSFECTION; VERO CELLS;

SIMPLEXVIRUS;

EID: 78449298941     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110372804     Document Type: Article

References (12)

1. Smith JS, Robinson NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002 ; 186 (suppl 1). S3-S28.
2. Arduino PG, Porter SR: Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 2008 ; 37: 107-121.
3. Chilukuri S., Rosen T.: Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 2003 ; 21: 311-320.
4. Field HJ: Herpes simplex virus antiviral drug resistance: current trends and future prospects. J Clin Virol 2001 ; 21: 261-269.
5. Danve-Szatanek C., Aymard M., Thouvenot D., Morfin F., Agius G., Bertin I.,, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004 ; 42: 242-249.
6. Tanaka M., Kodaira H., Nishiyama Y., Sata T., Kawaguchi Y.: Construction of recombinant herpes simplex virus type I expressing green fluorescent protein without loss of any viral genes. Microbes Infect 2004 ; 6: 485-493.
7. Wang YC, Kao CL, Liu WT, Sun JR, Tai YE, Kung SH: A cell line that secretes inducibly a reporter protein for monitoring Herpes simplex virus infection and drug susceptibility. J Med Virol 2002 ; 68: 599-605.
8. Stranska R., Schuurman R., Scholl DR, Jollick JA, Shaw CJ, Loef C.,, et al. ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing. Antimicrob Agents Chemother 2004 ; 48: 2331-2333.
9. Ho DY, Mocarski ES: Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse. Virology 1988 ; 167: 279-283.
10. Peng T., Ponce-de-Leon M., Jiang H., Dubin G., Lubinski JM, Eisenberg RJ,, et al. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J Virol 1998 ; 72: 65-72.
11. Dubin G., Jiang H.: Expression of herpes simplex virus type 1 glycoprotein L (gL) in transfected mammalian cells: evidence that gL is not independently anchored to cell membranes. J Virol 1995 ; 69: 4564-4568.
12. Nicola AV, Ponce de Leon M., Xu R., Hou W., Whitbeck JC, Krummenacher C.,, et al. Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM. J Virol 1998 ; 72: 3595-3601.